about
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritisFunctional analysis of an arthritogenic synovial fibroblastTargeting TNF receptors in rheumatoid arthritisIdentification of Naf1/ABIN-1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleotide microarraysTumor necrosis factor-alpha in temporomandibular joint synovial fluid predicts treatment effects on pain by intra-articular glucocorticoid treatment.Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculusThe protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis.Synovial fluid concentration of five different cytokines in rheumatic diseasesRole of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies.A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis.Synovial cell death is regulated by TNF-α-induced expression of B-cell activating factor through an ERK-dependent increase in hypoxia-inducible factor-1αAnti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distributionClinical significance of cytokine determination in synovial fluid.Treatment of rheumatoid arthritis with tumour necrosis factor inhibitorsDiverse expression of selected cytokines and proteinases in synovial fluid obtained from osteoarthritic and healthy human knee joints.The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis.Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants.Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.Silencing MicroRNA-155 Attenuates Cardiac Injury and Dysfunction in Viral Myocarditis via Promotion of M2 Phenotype Polarization of MacrophagesProduction of reactive oxygen (H2O2) and nitrogen (NO) intermediates and tnf-α in mice genetically selected for high (H) and low (L) antibody response and experimentally infected with Leptospira serovar pomona.Phytochemical Compositions and Antioxidant and Anti-Inflammatory Activities of Crude Extracts from Ficus pandurata H. (Moraceae).Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.Etanercept-Synthesising Mesenchymal Stem Cells Efficiently Ameliorate Collagen-Induced Arthritis.Regulatory T-cell vaccination independent of auto-antigen.Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.Anti-TNF in rheumatoid arthritis: an overview.Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity.Effects of Extract from Mangifera indica Leaf on Monosodium Urate Crystal-Induced Gouty Arthritis in Rats.Immunoregulatory role of interleukin 10 in rheumatoid arthritis.Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis.Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery.Combined effects of tumor necrosis factor-α and interleukin-1β on lysyl oxidase and matrix metalloproteinase expression in human knee synovial fibroblasts in vitro.LAIR-1 shedding from human fibroblast-like synoviocytes in rheumatoid arthritis following TNF-α stimulation.Visfatin Promotes IL-6 and TNF-α Production in Human Synovial Fibroblasts by Repressing miR-199a-5p through ERK, p38 and JNK Signaling Pathways.TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.
P2860
Q24564656-8EA47183-1CD6-45BE-8DC5-C6F656A19B91Q24804432-B0EA68C3-8030-4291-B275-9E21129E8C53Q26853279-5C09CC52-14DC-435B-8A55-AA435DB854A3Q28205951-392274C5-2717-4613-8530-016DF7C9A429Q30500767-07A66046-AB88-4002-9FDF-9513521C0105Q33287342-9EB78058-4D1F-42A8-905D-3AB30D51DDADQ33527432-6FD4FB94-B5E2-4527-9CF0-32CDC7B319E3Q33562942-EDC9FD2E-99A4-4900-AFD3-0A14A9480BB9Q33567277-49DDDA2F-6704-4CD6-AA65-B898BB97C579Q33578184-9826B547-4AA6-49F1-A58A-22351F06DB21Q33815933-DD34E2C1-3251-4E97-B64F-022E6FED15B8Q33966333-90474953-0558-4B29-8BE6-C2ABE16C3E3CQ34076916-54B31CC8-B275-4A72-AD4A-D3298A6994B9Q34184316-9E233147-EE5B-4065-B4AD-FAAE723EC9A6Q34559795-E874BF03-6120-4AC2-8863-9EA7ABEB41B4Q34588629-C06BB930-B21D-4463-BED1-BDD5CF862AE1Q34677275-02C3912B-9B32-4D99-867B-4A6BD7DC41EDQ35164732-B1E11B99-4B93-4840-936E-8C1C9C9B5E0BQ35605628-A64A02AF-BFC7-4441-93DF-C0D4BB90FD12Q35686603-EA08A66A-1474-4BEF-B127-FA2711BC5683Q36082965-594455BF-EEA3-4557-B3A9-1594713E820CQ36230900-39E2C831-A732-4832-A037-29238B3D705CQ36363302-C7936603-85C5-423D-8AE8-4DF2CD375503Q36638515-FC380F85-7E92-4C9B-85FE-A8FBBAD4C05AQ37162249-232ACF66-81BD-4C0D-BB14-B942012525B5Q37244081-DC187E78-7231-4233-B348-F92A6107FEDDQ37519964-85545696-3957-40A0-9CEC-8D4B7095B2F6Q37584714-9DCD88C4-5D54-45DF-8134-CD239CC28CB1Q37679455-022CDDB4-B814-4B69-A6C8-91AF38AB72B1Q37768849-903CD41E-125F-474C-9D11-80148BD41823Q38344282-4BE3E11B-BE9B-4805-998F-F1DFF9FF9954Q40594302-9E556899-9902-49C8-816A-5E0C90342931Q42280285-418BF65B-B49D-475E-AC07-90DDE5E3DCE2Q42942352-A8AD1B3E-29D6-4555-B99A-20080A993C5AQ44461538-9CD90100-0F99-4D02-82EF-3322AF6F9745Q45868500-E5BA0E5A-1902-4BAE-B9DE-1DD3AEB7FB98Q47159263-708B9784-63B7-4C6F-BA14-2684BEC858A7Q48254175-B1CD9268-0608-4D66-B6B0-579E26D84EB5Q48278219-44E3E10D-1101-49F9-882D-494819DBFD6BQ48319094-DA6F43C8-9420-47CC-BBCF-549C648386D5
P2860
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Tumour necrosis factor in synovial exudates.
@en
type
label
Tumour necrosis factor in synovial exudates.
@en
prefLabel
Tumour necrosis factor in synovial exudates.
@en
P2093
P2860
P356
P1476
Tumour necrosis factor in synovial exudates.
@en
P2093
P2860
P304
P356
10.1136/ARD.47.9.768
P407
P577
1988-09-01T00:00:00Z